Cytogen reports on Quadramet status
Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the company’s bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont
Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the companys bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont Pharmaceuticals to expedite the changeover, according to the company. North Billerica, MA-based Du Pont will continue to manufacture Quadramet.
The two companies initiated an interim agreement June 2 in which they determined that Du Pont would identify marketing partner candidates for Cytogen (SCAN Special Report 6/98). The agreement has been extended through the end of this month, pending the final selection of a new partner and the completion of Cytogens marketing arrangements with Du Pont. Cytogen has taken over the identification and selection of candidates as the process continues.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
